Drug Details
| General Information of the Drug (ID: DR3924) | ||||
|---|---|---|---|---|
| Name |
Bis(7)-tacrine
|
|||
| Synonyms |
bis(7)-Tacrine; 224445-12-9; 9-Amino-1,2,3,4-tetrahydroacridine bis 1,7-heptylene dihydrochloride; Tacrine-Based Inhibitor 2f; N,N/'-bis(1,2,3,4-tetrahydroacridin-9-yl)heptane-1,7-diamine;dihydrochloride; C33H40N4.2HCl; CHEMBL3752685; DTXSID80433317; 1640AH; SR-01000946720; SR-01000946720-1; Bis(heptyl)-cognitin dihydrochloride, >=98% (HPLC); 9-Amino-1,2,3,4-tetrahydroacridine bis 1,7-heptylene dihydrochloride, >97%, solid
Click to Show/Hide
|
|||
| Molecular Type |
Small molecule
|
|||
| Disease | Glaucoma [ICD-11: 9C61] | Investigative | [1] | |
| Structure |
|
Click to Download Mol2D MOL |
||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
| Formula |
C33H42Cl2N4
|
|||
| PubChem CID | ||||
| Canonical SMILES |
C1CCC2=NC3=CC=CC=C3C(=C2C1)NCCCCCCCNC4=C5CCCCC5=NC6=CC=CC=C64.Cl.Cl
|
|||
| InChI |
1S/C33H40N4.2ClH/c1(2-12-22-34-32-24-14-4-8-18-28(24)36-29-19-9-5-15-25(29)32)3-13-23-35-33-26-16-6-10-20-30(26)37-31-21-11-7-17-27(31)33;;/h4,6,8,10,14,16,18,20H,1-3,5,7,9,11-13,15,17,19,21-23H2,(H,34,36)(H,35,37);2*1H
|
|||
| InChIKey |
RHKXINFBJWDTSK-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 224445-12-9
|
|||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Natural Product(s) Able to Decrease the Adverse Effect of This Drug | ||||||
| Schisandrol B | Schisandra chinensis | Click to Show/Hide the Molecular Data of This NP | ||||
| Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| In-vivo Model | In the Sch B pretreatment group in the hepatotoxicity study, mice (Adult male ICR mice) were treated intragastrically with Sch B at daily doses of 0.125 and 0.5 mmol/kg for 3 days. | |||||
| Experimental
Result(s) |
Sch B may be useful for reducing the potential hepatotoxicity of THA/bis(7)-THA in anti-Alzheimer's therapy. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | Glutamate receptor ionotropic NMDA 2A (NMDAR2A) | Molecule Info | [1] | |
| Glutamate receptor ionotropic NMDA 2B (NMDAR2B) | Molecule Info | [1] | ||
| KEGG Pathway | Ras signaling pathway | Click to Show/Hide | ||
| 2 | Rap1 signaling pathway | |||
| 3 | Calcium signaling pathway | |||
| 4 | cAMP signaling pathway | |||
| 5 | Neuroactive ligand-receptor interaction | |||
| 6 | Circadian entrainment | |||
| 7 | Long-term potentiation | |||
| 8 | Glutamatergic synapse | |||
| 9 | Dopaminergic synapse | |||
| 10 | Alzheimer's disease | |||
| 11 | Amyotrophic lateral sclerosis (ALS) | |||
| 12 | Cocaine addiction | |||
| 13 | Amphetamine addiction | |||
| 14 | Nicotine addiction | |||
| 15 | Alcoholism | |||
| 16 | Systemic lupus erythematosus | |||
| 17 | Huntington's disease | |||
| Panther Pathway | Huntington disease | Click to Show/Hide | ||
| 2 | Ionotropic glutamate receptor pathway | |||
| 3 | Metabotropic glutamate receptor group III pathway | |||
| 4 | Metabotropic glutamate receptor group I pathway | |||
| 5 | Muscarinic acetylcholine receptor 1 and 3 signaling pathway | |||
| Pathway Interaction Database | Reelin signaling pathway | Click to Show/Hide | ||
| 2 | ErbB4 signaling events | |||
| Reactome | Unblocking of NMDA receptor, glutamate binding and activation | Click to Show/Hide | ||
| 2 | CREB phosphorylation through the activation of CaMKII | |||
| 3 | Ras activation uopn Ca2+ infux through NMDA receptor | |||
| 4 | RAF/MAP kinase cascade | |||
| 5 | EPHB-mediated forward signaling | |||
| WikiPathways | Hypothetical Network for Drug Addiction | Click to Show/Hide | ||
| 2 | Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell | |||
| 3 | Alzheimers Disease | |||
| 4 | BDNF signaling pathway | |||
